As previously reported, Scotiabank upgraded Beam Therapeutics (BEAM) to Outperform from Sector Perform with a price target of $40, up from $25, following positive data from part A of the Phase 1/2 trial of BEAM-302 in alpha-1 antitrypsin deficiency. The firm thinks the data were “a clear win for Beam in AATD,” which it views as “an underappreciated market opportunity,” the analyst told investors.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BEAM:
- Cathie Wood’s ARK Investment buys 485K shares of Beam Therapeutics today
- JonesResearch upgrades Beam Therapeutics to Buy on de-risking data
- Beam Therapeutics upgraded to Buy from Hold at JonesResearch
- Beam data ‘encouraging,’ support continuation of trial, says H.C. Wainwright
- Promising Phase 1/2 Trial Results for Beam Therapeutics’ BEAM-302 Bolster Confidence and Support $80 Price Target